News & Events about Avidity Biosciences Inc.
NEW YORK, April 24, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Avidity Biosciences, Inc. (Avidity or the Company) (NASDAQ: RNA). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. The ...
Avidity Biosciences Granted FDA Fast Track Designation for AOC 1044 for Treatment of Duchenne Muscular Dystrophy Mutations Amenable to Exon 44 Skipping Avidity Biosciences Granted FDA Fast Track Designation for AOC 1044 for Treatment of Duchenne Muscular Dystrophy Mutations Amenable to Exon 44...
ATLANTA, April 20, 2023 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Avidity Biosciences, Inc. (Avidityor the Company) (NASDAQ: RNA) complied with federal securities laws. On March 30, 2023, Avidity provided an update on its product that is on a partial clinical hold for new ...
Avidity Biosciences Announces Upcoming Presentations at the 75th American Academy of Neurology Annual Meeting Avidity Biosciences Announces Upcoming Presentations at the 75th American Academy of Neurology Annual Meeting PR Newswire SAN DIEGO, April 17, 2023 SAN DIEGO, April 17, 2023 /PRNewswire...
Avidity Biosciences to Host Investor and Analyst Event Focused on AOC 1001 Topline Data from Phase 1/2 MARINA Trial on April 27, 2023 Avidity Biosciences to Host Investor and Analyst Event Focused on AOC 1001 Topline Data from Phase 1/2 MARINA Trial on April 27, 2023 PR Newswire SAN DIEGO...